The Pharmaceutical Journal
Vol 269 No 7229 p879
21/28 December 2002

This article
Reprint
Photocopy

News summary

Anastrozole benefit continues

Follow-up data from the Arimidex, tamoxifen alone or in combination (ATAC) study show that women treated with anastrozole (Arimidex) are more likely to be disease-free at four years than women treated with tamoxifen.

The data also show that the percentage of patients remaining disease-free for longer on anastrozole in comparison with tamoxifen has increased since the last analysis, from 2.0 per cent at three years to 2.4 per cent at four years. Data were presented at a San Antonio breast cancer symposium last week.